1. Home
  2. SCYX vs AIXI Comparison

SCYX vs AIXI Comparison

Compare SCYX & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • AIXI
  • Stock Information
  • Founded
  • SCYX 1999
  • AIXI 2001
  • Country
  • SCYX United States
  • AIXI China
  • Employees
  • SCYX N/A
  • AIXI N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • AIXI Computer Software: Prepackaged Software
  • Sector
  • SCYX Health Care
  • AIXI Technology
  • Exchange
  • SCYX Nasdaq
  • AIXI Nasdaq
  • Market Cap
  • SCYX 28.5M
  • AIXI 31.2M
  • IPO Year
  • SCYX 2014
  • AIXI 2023
  • Fundamental
  • Price
  • SCYX $0.70
  • AIXI $1.80
  • Analyst Decision
  • SCYX
  • AIXI
  • Analyst Count
  • SCYX 0
  • AIXI 0
  • Target Price
  • SCYX N/A
  • AIXI N/A
  • AVG Volume (30 Days)
  • SCYX 182.9K
  • AIXI 229.1K
  • Earning Date
  • SCYX 08-07-2025
  • AIXI 05-15-2025
  • Dividend Yield
  • SCYX N/A
  • AIXI N/A
  • EPS Growth
  • SCYX N/A
  • AIXI N/A
  • EPS
  • SCYX N/A
  • AIXI N/A
  • Revenue
  • SCYX $2,630,000.00
  • AIXI $70,314,315.00
  • Revenue This Year
  • SCYX $410.22
  • AIXI $26.84
  • Revenue Next Year
  • SCYX $248.83
  • AIXI N/A
  • P/E Ratio
  • SCYX N/A
  • AIXI N/A
  • Revenue Growth
  • SCYX N/A
  • AIXI 18.84
  • 52 Week Low
  • SCYX $0.66
  • AIXI $1.77
  • 52 Week High
  • SCYX $2.21
  • AIXI $8.31
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 43.16
  • AIXI 36.26
  • Support Level
  • SCYX $0.67
  • AIXI $1.76
  • Resistance Level
  • SCYX $0.74
  • AIXI $2.36
  • Average True Range (ATR)
  • SCYX 0.04
  • AIXI 0.24
  • MACD
  • SCYX 0.00
  • AIXI -0.01
  • Stochastic Oscillator
  • SCYX 18.79
  • AIXI 5.28

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About AIXI XIAO-I Corporation

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

Share on Social Networks: